🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Fianlimab

    Regeneron UK Limited

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  3. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Fluorouracil Injection 25 mg/ml, solution for injection, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  5. Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, LEVOFOLENE 175 mg polvere per soluzione per infusione

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  6. Folfox plus Bevacizumab and reolysin

    ONCOLYTICS BIOTECH INC

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  7. Folinezuur Kalceks 10 mg/ml oplossing voor injectie/infusie, Paclitaxel Fresenius Kabi 6 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie, Docetaxel Eugia 20 mg/ml, concentraat voor oplossing voor intraveneuze infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 small molecule active

    1 trial

  8. Forxiga 10 mg film-coated tablets

    Fondazione Telethon ETS

    Chemotherapy-induced cardiotoxicity in breast cancer

    phase 2 small molecule active

    1 trial

  9. Fruquintinib

    Dai, Guanghai

    Colorectal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  10. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  11. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  12. Fulvestrant

    Syndax Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  13. Fulvestrant

    United Therapeutics Europe Ltd

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 100 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules

    Pfizer Australia Pty Ltd

    Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)

    phase 2 small molecule active

    1 trial

  15. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  16. Fulvestrant with Enzalutamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  17. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  18. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. GC4419

    Galera Therapeutics

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. GEMCITABINE, PACLITAXEL, PACLITAXEL

    Fondazione Telethon ETS

    Pancreatic cancer with peritoneal metastases

    phase 2 small molecule active

    1 trial

  22. GEMZAR 200 mg, poudre pour solution pour perfusion, ACR-368

    Acrivon Therapeutics

    Endometrial cancer

    phase 2 small molecule active

    1 trial

  23. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    2 trials

  24. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Cancer of the Bile Duct

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources